tiprankstipranks
Gilead Sciences (GILD)
NASDAQ:GILD
US Market
GILD
Gilead Sciences
RESEARCH TOOLSreports
Want to see GILD full AI Analyst Report?

Gilead Sciences (GILD) Stock Forecast & Price Target

13,955 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
20Ratings
Strong Buy
17 Buy
3 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$159.79
▲(16.09% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $159.79 with a high forecast of $180.00 and a low forecast of $120.00. The average price target represents a 16.09% change from the last price of $137.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"107":"$107","144":"$144","181":"$181","125.5":"$125.5","162.5":"$162.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":159.78947368421052,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$159.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$120.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[107,125.5,144,162.5,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.97,130.12615384615384,134.28230769230768,138.43846153846152,142.5946153846154,146.75076923076924,150.90692307692308,155.06307692307692,159.21923076923076,163.37538461538463,167.53153846153845,171.68769230769232,175.84384615384616,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.97,128.5714979757085,131.172995951417,133.7744939271255,136.37599190283402,138.9774898785425,141.578987854251,144.1804858299595,146.781983805668,149.3834817813765,151.984979757085,154.58647773279353,157.18797570850202,{"y":159.78947368421052,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.97,125.51076923076923,125.05153846153846,124.59230769230768,124.13307692307693,123.67384615384616,123.21461538461539,122.75538461538461,122.29615384615384,121.83692307692307,121.37769230769231,120.91846153846154,120.45923076923077,{"y":120,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":108.893,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.306,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.101,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.559,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.014,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.155,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.208,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.383,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.244,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.97,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$159.79Lowest Price Target$120.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
17.70%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$165
Buy
19.88%
Upside
Reiterated
07/09/26
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
J.P. Morgan Analyst forecast on GILD
Chris Schott
J.P. Morgan
J.P. Morgan
$160
Buy
16.25%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT), Ionis Pharmaceuticals (NASDAQ: IONS) and Gilead Sciences (NASDAQ: GILD)
Morgan Stanley Analyst forecast on GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$168→$166
Buy
20.60%
Upside
Reiterated
07/08/26
Gilead price target lowered to $166 from $168 at Morgan StanleyGilead price target lowered to $166 from $168 at Morgan Stanley
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$122→$120
Hold
-12.82%
Downside
Reiterated
07/07/26
Gilead price target lowered to $120 from $122 at RBC CapitalGilead price target lowered to $120 from $122 at RBC Capital
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
$157→$156
Buy
13.34%
Upside
Reiterated
07/07/26
Gilead price target lowered to $156 from $157 at TruistGilead price target lowered to $156 from $157 at Truist
HSBC Analyst forecast on GILD
Morten Herholdt
HSBC
HSBC
$133→$155
Buy
12.61%
Upside
Upgraded
07/06/26
Gilead upgraded to Buy from Hold at HSBCGilead upgraded to Buy from Hold at HSBC
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
28.60%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (NASDAQ: SPRY), Gilead Sciences (NASDAQ: GILD) and Icon (NASDAQ: ICLR)
Cantor Fitzgerald Analyst forecast on GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$155
Buy
12.61%
Upside
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (NASDAQ: GALT) and Gilead Sciences (NASDAQ: GILD)
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$165
Buy
19.88%
Upside
Reiterated
06/17/26
Gilead Sciences (GILD) Receives a Buy from Citi
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
23.51%
Upside
Assigned
06/12/26
Gilead Sciences (GILD) Gets a Buy from Needham
Mizuho Securities Analyst forecast on GILD
Salim Syed
Mizuho Securities
Mizuho Securities
$170
Buy
23.51%
Upside
Reiterated
06/12/26
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Bernstein Analyst forecast on GILD
Courtney Breen
Bernstein
Bernstein
$160
Buy
16.25%
Upside
Reiterated
06/09/26
Gilead Sciences (GILD) Gets a Buy from Bernstein
Jefferies Analyst forecast on GILD
Akash Tewari
Jefferies
Jefferies
$180
Buy
30.78%
Upside
Reiterated
05/22/26
Jefferies Remains a Buy on Gilead Sciences (GILD)
Maxim Group Analyst forecast on GILD
Michael Okunewitch
Maxim Group
Maxim Group
$165
Buy
19.88%
Upside
Upgraded
05/20/26
Gilead upgraded to Buy from Hold at MaximGilead upgraded to Buy from Hold at Maxim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$162
Buy
17.70%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$165
Buy
19.88%
Upside
Reiterated
07/09/26
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
J.P. Morgan Analyst forecast on GILD
Chris Schott
J.P. Morgan
J.P. Morgan
$160
Buy
16.25%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT), Ionis Pharmaceuticals (NASDAQ: IONS) and Gilead Sciences (NASDAQ: GILD)
Morgan Stanley Analyst forecast on GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$168→$166
Buy
20.60%
Upside
Reiterated
07/08/26
Gilead price target lowered to $166 from $168 at Morgan StanleyGilead price target lowered to $166 from $168 at Morgan Stanley
RBC Capital Analyst forecast on GILD
Brian Abrahams
RBC Capital
RBC Capital
$122→$120
Hold
-12.82%
Downside
Reiterated
07/07/26
Gilead price target lowered to $120 from $122 at RBC CapitalGilead price target lowered to $120 from $122 at RBC Capital
Truist Financial Analyst forecast on GILD
Gregory Renza
Truist Financial
Truist Financial
$157→$156
Buy
13.34%
Upside
Reiterated
07/07/26
Gilead price target lowered to $156 from $157 at TruistGilead price target lowered to $156 from $157 at Truist
HSBC Analyst forecast on GILD
Morten Herholdt
HSBC
HSBC
$133→$155
Buy
12.61%
Upside
Upgraded
07/06/26
Gilead upgraded to Buy from Hold at HSBCGilead upgraded to Buy from Hold at HSBC
Scotiabank Analyst forecast on GILD
Louise Chen
Scotiabank
Scotiabank
$177
Buy
28.60%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (NASDAQ: SPRY), Gilead Sciences (NASDAQ: GILD) and Icon (NASDAQ: ICLR)
Cantor Fitzgerald Analyst forecast on GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$155
Buy
12.61%
Upside
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (NASDAQ: GALT) and Gilead Sciences (NASDAQ: GILD)
Citi Analyst forecast on GILD
Geoff Meacham
Citi
Citi
$165
Buy
19.88%
Upside
Reiterated
06/17/26
Gilead Sciences (GILD) Receives a Buy from Citi
Needham Analyst forecast on GILD
Joseph Stringer
Needham
Needham
$170
Buy
23.51%
Upside
Assigned
06/12/26
Gilead Sciences (GILD) Gets a Buy from Needham
Mizuho Securities Analyst forecast on GILD
Salim Syed
Mizuho Securities
Mizuho Securities
$170
Buy
23.51%
Upside
Reiterated
06/12/26
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Bernstein Analyst forecast on GILD
Courtney Breen
Bernstein
Bernstein
$160
Buy
16.25%
Upside
Reiterated
06/09/26
Gilead Sciences (GILD) Gets a Buy from Bernstein
Jefferies Analyst forecast on GILD
Akash Tewari
Jefferies
Jefferies
$180
Buy
30.78%
Upside
Reiterated
05/22/26
Jefferies Remains a Buy on Gilead Sciences (GILD)
Maxim Group Analyst forecast on GILD
Michael Okunewitch
Maxim Group
Maxim Group
$165
Buy
19.88%
Upside
Upgraded
05/20/26
Gilead upgraded to Buy from Hold at MaximGilead upgraded to Buy from Hold at Maxim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Tyler Van BurenTD Cowen
Success Rate
24/31 ratings generated profit
77%
Average Return
+7.59%
Copying Tyler Van Buren's trades and holding each position for 3 Months would result in 77.42% of your transactions generating a profit, with an average return of +7.59% per trade.
1 Year
Geoff MeachamCiti
Success Rate
20/23 ratings generated profit
87%
Average Return
+23.55%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +23.55% per trade.
2 Years
Chris SchottJ.P. Morgan
Success Rate
22/24 ratings generated profit
92%
Average Return
+40.57%
Copying Chris Schott's trades and holding each position for 2 Years would result in 91.67% of your transactions generating a profit, with an average return of +40.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
50
48
41
58
46
Hold
10
13
12
13
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
60
61
53
71
55
In the current month, GILD has received 46 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 159.79.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is -$7.31 with a range of -$7.93 to -$6.40. The previous quarter’s EPS was $2.03. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for GILD is -$7.31 with a range of -$7.93 to -$6.40. The previous quarter’s EPS was $2.03. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $7.40B with a range of $7.18B to $7.65B. The previous quarter’s sales results were $6.98B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for GILD is $7.40B with a range of $7.18B to $7.65B. The previous quarter’s sales results were $6.98B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 159.79.
    What is GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 16.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GILD a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s price target?
            The average price target for Gilead Sciences is 159.79. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $180.00 ,the lowest forecast is $120.00. The average price target represents 16.09% Increase from the current price of $137.64.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of GILD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.